TLE1 Expression in Different Sarcoma Types and its Relation to Clinicopathological Parameters
DOI:
https://doi.org/10.56056/amj.2024.288Keywords:
Immunohistochemistry, Synovial sarcoma, TLE1Abstract
Background and objectives: Split genes that contain Transducin-Like Enhancer encode transcriptional corepressors that are essential for hematopoiesis and embryogenesis in humans. Synovial sarcomas express Transducin-Like Enhancer-1, a distinct factor which hardly has been shown in other soft tissues malignancies. Transducin-Like Enhancer-1 expression was recently found to be sensitive but not entirely specific for synovial sarcoma.
Methods: This retrospective study included eighty paraffin embedded formalin-fixed blocks of different sarcomas which were gathered and picked out of the files of Rizgary teaching hospital lab and from certain private labs in Hawler, during June 2015-December 2022. In this study, Transducin-Like Enhancer-1, a mouse monoclonal antibody was applied on sarcoma cases and its expression was assessed.
Results: around one third (30%) of the patients had synovial sarcoma, (16.3%) had undifferentiated pleomorphic sarcoma, and the rest had other types. More than half (55%) of the sarcomas were of high grade, and the Transducin-Like Enhancer-1 score was strongly reactive in 33.8% of the patients. It was also strong in all (100%) the patients with synovial sarcoma, compared with 23.1% of patients with undifferentiated pleomorphic sarcoma, and 0% of the other types of sarcoma (p < 0.001).
Conclusion: this study demonstrates that, when synovial sarcoma was kept in the differential diagnosis of spindle cell soft tissue sarcomas, Transducin-Like Enhancer-1 was a highly sensitive and relatively a specific marker.
Downloads
References
Burningham Z, Hashibe M, Spector L, Schiffman Joshua D . The epidemiology of sarcoma. Clin. Sarcoma Res. 2012;2(1):1-16.
Hussain Ashraf MA, Lafta Riyadh K. Cancer trends in Iraq 2000–2016. Oman Med. J. 2021;36(1):e219.
van Vliet M, Kliffen M, Krestin G, van Dijke CF. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur. Radiol. 2009;19:1499-511.
Qureshi MB, Uddin N, Tariq M, et al. Frequency of transducer-like enhancer of split 1 immunohistochemical expression in synovial sarcoma: an institution-based cross-sectional study. Cureus. 2019;11(12).
Qureshi MB, Tariq MU, Abdul-Ghafar J, Chundriger Q, Ud Din N. Diagnostic utility of TLE1 (transducer-like enhancer of split 1) in distinguishing synovial sarcoma from mimicking tumors. Int. J. Gen. Med. 2021:9173-9.
El Beaino M, Jupiter DC, Assi T, Rassy E, Lazar AJ, Araujo DM, et al. Diagnostic value of TLE1 in synovial sarcoma: a systematic review and meta-analysis. Sarcoma. 2020; 2020: 7192347.
Pinto K, Chetty R. Gene of the month: TLE 1. J. Clin. Pathol. 2021;74(3):137-40.
Seo SW, Lee H, Lee HI, Kim HS. The role of TLE1 in synovial sarcoma. J. Orthop. Res. 2011;29(7):1131-6.
Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am. J. Surg. Pathol. 2007;31(2):240-6.
Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. J. Mod. Hum. Pathol. 2009;22(7):872-8.
Knösel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t (X; 18): analysis of 319 cases. Eur. J. Cancer. 2010;46(6):1170-6.
Foo WC, Cruise MW, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am. J. Clin. Pathol. 2011;135(6):839-44.
Rekhi B, Basak R, Desai SB, Jambhekar NA. Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas. IJMR. 2012;136(5):766.
Ali Z, Khan AH, Rehman U, Faisal M, Ahmad IN, Mamoon N, et al. Is TLE1 expression limited to synovial sarcoma Our experience at shifa international hospital, Pakistan. Cureus. 2019;11(11).
Atef A, Alrashidy M. Transducer-like enhancer of split 1 as a novel immunohistochemical marker for diagnosis of synovial sarcoma. APJCP. 2015;16(15):6545-8.
Bakrin IH, Hussain FA, Sharif ST. Transducer-like enhancer of split 1 (TLE1) expression as a diagnostic immunohistochemical marker for synovial sarcoma and its association with morphological features. Malays. J. Pathol. 2016;38(2):117-22.
Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am. J. Surg. Pathol. 2009;33(12):1743-51.
He X, Xiong B, Zhou T, Lan T, Chen M, Chen H, et al. Diagnostic value of TLE1 for synovial sarcoma: immunohistochemical analyses of genetically confirmed synovial sarcomas and nonsynovial sarcomas. Int J Clin Exp Pathol. 2016;9(4):4339-50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Toqa Jabbar Chckaim, Saman Salah Eldeen Abdulla, Savan Saeed Azeez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
